NCT06015269招募中1 期
Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity
研究概览
简要总结
This is an exploratory study on the safety, immune response, and preliminary effectiveness of single arm, fixed dose therapy
详细描述
This study is a clinical study exploring the safety, immune response, and preliminary efficacy of a single arm, 1x107cells dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-80 years old, weight ≥ 40kg; No gender limit;
- •Subjects with malignant solid tumors diagnosed by histology or cytology and undergoing radical resection surgery;
- •At the beginning of the study (after surgery), there were no lesions, no local recurrence or distant metastasis on the imaging, and no brain metastasis (images within one month before enrollment can be used for screening);
- •Subjects in the safety verification stage need to provide immunohistochemical test results with positive expression of Survivin or P53;
- •ECOG score 0-1 points;
- •There are sufficient venous channels and no contraindications for peripheral blood mononuclear cell collection surgery;
- •Organs and bone marrow function well:
- •Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% evaluated by echocardiography within one month of enrollment; The electrocardiogram is basically normal;
- •Platelets ≥ 90 × 10 ^ 9/L;
- •Hemoglobin ≥ 90g/L (no blood transfusion or erythropoietin dependence within 7 days);
- •Total bilirubin ≤ 2 times the upper limit of normal value;
- •Serum creatinine ≤ 1.5 times the upper limit of normal value;
- •Transaminases (AST, ALT) ≤ 2.5 times the upper limit of normal value (if liver cancer is 5 times the upper limit of normal value);
- •International standardized ratio (INR) or prothrombin time (PT) ≤ 1.5 times the upper limit of normal value;
- •Pulmonary function: ≤ CTCAE level 1 dyspnea and SaO2 ≥ 91% in indoor air environment;
- •Able to understand trial requirements and matters, willing to participate in clinical research according to trial requirements;
排除标准
- •HIV and syphilis serological reactions were positive; Hepatitis B surface antigen is positive, hepatitis B core antibody is positive, and the copy number of hepatitis B virus DNA is higher than the lower limit of detection and or greater than or equal to 1000 copies/ml; Or hepatitis C virus infected individuals;
- •Any uncontrollable active infection, coagulation disorder, or any other major disease;
- •Pregnant or lactating women
- •Suffering from active neuroautoimmune or inflammatory diseases, such as any of the following: inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, multiple sclerosis, Sjogren's syndrome, etc., and receiving relevant treatment; Subjects who are still using immunosuppressants for organ transplantation; Or subjects who have been using immunosuppressive drugs such as glucocorticoids for a long time cannot stop at least 4 weeks before enrollment; Severe allergic constitution;
- •Subjects with existing abnormalities in the central nervous system, such as seizures, cerebral vascular ischemia/bleeding, dementia, cerebellar diseases, or any autoimmune diseases associated with central nervous system involvement;
- •Major cardiovascular diseases with clinical significance include:
- •Symptomatic congestive heart failure
- •B Unstable angina pectoris
- •Severe arrhythmia requiring medication treatment
- •Uncontrolled hypertension
- •Myocardial infarction or ventricular arrhythmia within 6 months prior to screening
- •Other situations where researchers believe it is not suitable to participate in clinical trials.
研究组 & 干预措施
DC cells
Experimental
Super DC Vaccine (DC)
干预措施: DC cells (Drug)
结局指标
主要结局
Dose-limiting toxicity
时间窗: within 1 months of single injection
Safety
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After SurgeryGlioblastoma Multiforme of BrainNCT04968366Beijing Tiantan Hospital11
终止
1 期
Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic SynovitisSynovitisHemophiliaNCT02060305National Taiwan University Hospital5
已完成
2 期
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis SuppurativaNCT05093855Staidson (Beijing) Biopharmaceuticals Co., Ltd41
Unknown
1 期
DC Vaccine Combined With CIK Cells in Patients With Renal Cell CarcinomaRenal Cell CarcinomaNCT01924156Affiliated Hospital to Academy of Military Medical Sciences30
招募中
1 期
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast CancerTriple Negative Breast CancerHER2-negative Breast CancerNCT05504707H. Lee Moffitt Cancer Center and Research Institute30